FindTrial
Sign In

Real World Evidence study of isavuconazole efficacy and safety in treatment of invasive aspergillosis and mucormycosis in adults

A non comparative , multi centre observational study: Isavuconazole (Cresemba) in Invasive Mould Infections (Invasive Aspergillosis, Invasive Mucormycosis) in India

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/11/038216
Enrollment
70
Registered
2021-11-23
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J709- Respiratory conditions due to unspecified external agent

Interventions

Intervention1: NIL: Treatment of invasive aspergillosis and mucormycosis with isavuconazole in adults

Sponsors

Pfizer
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients 18 years or older 2. Patients with diagnosis of invasive aspergillosis/invasive mucormycosis meeting the criteria for proven, probable or possible invasive mould disease as per the judgement of the treating physician and must have received Cresemba for at least 48h .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Safety of isavuconazole in the treatment of invasive aspergillosis and mucormycosis in adultsTimepoint: 6 weeks—

Secondary

MeasureTime frame
Effectiveness of isavuconazole in the treatment of invasive aspergillosis and mucormycosis in adultsTimepoint: 6 weeks—

Countries

India

Contacts

Public ContactDr Prithwijit Kundu

Pfizer Limited

Prithwijit.Kundu@pfizer.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026